Lucie E. Lovelle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lucie E. Lovelle has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Alan Steven
Process Chemist
3 shared publications - Jack A. Terrett
Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
3 shared publications Jingjun Yin
Merck and Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
3 shared publications- John Hayler
Chemical Development, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, United Kingdom
3 shared publications - Kenneth J. Fraunhoffer
Chemical Process Development Bristol-Myers Squibb New Brunswick New Jersey 08903 USA
3 shared publications Marie-Gabrielle Braun
Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
3 shared publications
Latest Publications
- 16 April 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (6) , 897-908
Green Chemistry Articles of Interest to the Pharmaceutical Industry
- 16 April 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (6) , 897-908
Green Chemistry Articles of Interest to the Pharmaceutical Industry
- 2 March 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (3) , 334-346
Green Chemistry Articles of Interest to the Pharmaceutical Industry
- 2 March 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (3) , 334-346
Green Chemistry Articles of Interest to the Pharmaceutical Industry
- 6 November 2019
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 23 (11) , 2287-2301
Green Chemistry Articles of Interest to the Pharmaceutical Industry
- 6 November 2019
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 23 (11) , 2287-2301
Green Chemistry Articles of Interest to the Pharmaceutical Industry
- Open Access
- 4 October 2019
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 23 (11) , 2470-2481
New Semi-Automated Computer-Based System for Assessing the Purge of Mutagenic Impurities
The ICH M7 guidance provides a series of flexible control options for the control of (potentially) mutagenic impurities (PMIs) that fully align with key risk-based principles. This includes Option 4, which leverages existing process knowledge and/or data to justify control of PMIs without the need for routine analytical release testing during manufacturing. One such technique highlighted uses systematic, semi-quantitative calculations to define the degree of “purge” of PMIs within a synthetic route to an API based on physicochemical properties of the impurities in question, and the manufacturing process being undertaken. This paper introduces a consortium-led initiative, Mirabilis, which aims to build on the semi-quantitative purge approach, and harmonize industry best practices by enabling the calculations to be conducted in a standardized, consistent and reproducible manner. The development of an expert-derived knowledge base for the prediction of reactivity by enhancing expert opinion using evidence derived from published literature and experimental data is also discussed. Furthermore, this paper describes the application of the Mirabilis software for the processes involved in the synthesis of Verbecestat, Naloxegol oxalate and Camicinal. Purge, ICH M7, mutagenic impurities, control options
- 4 October 2019
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 23 (11) , 2470-2481
Open AccessNew Semi-Automated Computer-Based System for Assessing the Purge of Mutagenic Impurities
The ICH M7 guidance provides a series of flexible control options for the control of (potentially) mutagenic impurities (PMIs) that fully align with key risk-based principles. This includes Option 4, which leverages existing process knowledge and/or data to justify control of PMIs without the need for routine analytical release testing during manufacturing. One such technique highlighted uses systematic, semi-quantitative calculations to define the degree of “purge” of PMIs within a synthetic route to an API based on physicochemical properties of the impurities in question, and the manufacturing process being undertaken. This paper introduces a consortium-led initiative, Mirabilis, which aims to build on the semi-quantitative purge approach, and harmonize industry best practices by enabling the calculations to be conducted in a standardized, consistent and reproducible manner. The development of an expert-derived knowledge base for the prediction of reactivity by enhancing expert opinion using evidence derived from published literature and experimental data is also discussed. Furthermore, this paper describes the application of the Mirabilis software for the processes involved in the synthesis of Verbecestat, Naloxegol oxalate and Camicinal. Purge, ICH M7, mutagenic impurities, control options